APCDD1L Inhibitors
APCDD1L inhibitors encompass a range of chemicals that interfere with signaling pathways instrumental in the regulation and activity of APCDD1L. Notably, most of the identified inhibitors target the Hedgehog signaling pathway, which is directly linked to the transcriptional regulation of APCDD1L. Cyclopamine, Jervine, and Vismodegib serve as classic examples of Hedgehog pathway inhibitors by their binding to Smoothened (SMO), a pivotal component of this signaling cascade. By occupying the SMO receptor, these compounds prevent the downstream activation of GLI transcription factors that are known to drive the expression of APCDD1L.
Analogously, Sonidegib and Saridegib are oral inhibitors that also target SMO, impeding the Hedgehog signaling and consequently the activity of APCDD1L. These compounds, through their interactions, showcase a direct relationship between the blockade of SMO and the resultant reduction in APCDD1L activity. Moreover, Itraconazole, while not initially developed as a Hedgehog pathway inhibitor, has demonstrated the ability to suppress APCDD1L by hindering the same pathway. Fluvastatin, though its primary use is unrelated to the Hedgehog pathway, has shown potential in inhibiting the pathway and therefore could contribute to the reduced activity of APCDD1L. This unexpected activity of fluvastatin offers insight into the diverse chemical interactions that can influence signaling pathways critical to APCDD1L function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine is a Hedgehog signaling pathway inhibitor that binds to Smoothened (SMO). By inhibiting SMO, it prevents the activation of GLI transcription factors, which are crucial for the transcription of APCDD1L, leading to decreased APCDD1L activity. | ||||||
Vismodegib | 879085-55-9 | sc-396759 sc-396759A | 10 mg 25 mg | $82.00 $158.00 | 1 | |
Vismodegib is a specific inhibitor of the Hedgehog signaling pathway that targets Smoothened (SMO). The inhibition of SMO impedes the transcriptional activation of Hedgehog target genes including APCDD1L, thereby reducing its activity. | ||||||
GANT61 | 500579-04-4 | sc-202630 sc-202630A sc-202630B | 1 mg 5 mg 10 mg | $64.00 $131.00 $204.00 | 6 | |
GANT61 is a GLI inhibitor that directly interferes with GLI-mediated transcription, a downstream component of the Hedgehog signaling pathway. This inhibition is expected to lower the transcription and activity of APCDD1L. | ||||||
Jervine | 469-59-0 | sc-200934 sc-200934A | 1 mg 5 mg | $66.00 $240.00 | 1 | |
Jervine is an inhibitor of the Hedgehog signaling pathway that acts similarly to cyclopamine by inhibiting SMO. This action blocks Hedgehog pathway signaling and downstream effects such as APCDD1L activity. | ||||||
Erismodegib | 956697-53-3 | sc-396280 sc-396280A | 10 mg 100 mg | $255.00 $918.00 | ||
Sonidegib is an oral Hedgehog pathway inhibitor that binds to and inhibits SMO. This inhibition prevents the activation of the Hedgehog pathway, resulting in a reduction of APCDD1L activity. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $78.00 $142.00 | 23 | |
Itraconazole has been found to inhibit the Hedgehog signaling pathway, albeit through mechanisms that are not completely understood. The inhibition of this pathway can suppress APCDD1L activity. | ||||||
Fluvastatin, Sodium Salt | 93957-55-2 | sc-202613 sc-202613A sc-202613B | 25 mg 50 mg 100 mg | $93.00 $138.00 $246.00 | 1 | |
Fluvastatin, while primarily known as a statin for cholesterol management, has been reported to inhibit Hedgehog signaling. This inadvertent inhibition can reduce APCDD1L activity by impeding the pathway it is involved in. | ||||||
Saridegib | 1037210-93-7 | sc-507351 | 5 mg | $3500.00 | ||
Saridegib is an inhibitor of SMO, which is part of the Hedgehog signaling pathway. By inhibiting SMO, it reduces the signaling that leads to APCDD1L activity. | ||||||
PF-5274857 | 1373615-35-0 | sc-478208 | 5 mg | $360.00 | ||
PF-5274857 is a potent and selective SMO inhibitor that targets the Hedgehog signaling pathway. The inhibition of SMO prevents the pathway's activation, leading to a decrease in APCDD1L activity. | ||||||